Palisade Bio shareholders elect directors, ratify accounting firm

Today, Palisade Bio, Inc., a biopharmaceutical company, held its annual meeting of stockholders, with key votes on the election of directors and the ratification of the company's independent registered public accounting firm.

Shareholders elected three directors to serve until the 2025 annual meeting or until their successors are appointed. J.D. Finley, Donald Williams, and Margery Fischbein were elected with 141,074, 139,029, and 142,588 votes for, respectively. Votes withheld were 11,984 for Finley, 14,029 for Williams, and 10,470 for Fischbein. There were 227,228 broker non-votes for each director.

In addition to the election of directors, shareholders ratified the appointment of Baker Tilly US, LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2024. The decision was made with 370,358 votes in favor, 7,697 against, and 2,231 withheld or abstained. There were no broker non-votes for this proposal.

The meeting saw a quorum with approximately 40.61% of the outstanding shares present in person or by proxy. The company, formerly known as Seneca Biopharma, Inc. and Neuralstem, Inc., is incorporated in Delaware and headquartered in Carlsbad, California.

In other recent news, biopharmaceutical company Palisade Bio has made notable advancements in its strategic collaboration with Strand Life Sciences, identifying potential PDE4-related biomarkers for ulcerative colitis (UC) treatment. The company has also secured a Canadian patent for its UC treatment, PALI-2108, and plans to initiate a Phase 1 clinical study by the end of 2024. Financial services firm Ladenburg Thalmann has maintained a Buy rating for Palisade Bio, highlighting the potential of PALI-2108 to improve clinical remission rates.

In addition, Palisade Bio has appointed Margery Fischbein to its Board of Directors, leveraging her extensive experience in healthcare investment banking and biotechnology. The company has also secured approximately $4 million in a private placement agreement with an institutional investor. These developments underscore Palisade Bio's ongoing efforts in the biopharmaceutical space.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.